SIR 2024
Interventional Oncology
Marios Platon Dimopoulos, MD,MSc
Resident
University Hospital of Patras, Greece
Disclosure information not submitted.
Nikos Giannikas, MD, MS
Resident
General University Hospital of Patras, Greece
Disclosure information not submitted.
George Nistikoulis, MD
Resident
General University Hospital of Patras, Greece
Disclosure information not submitted.
Trifon Spyridonidis, MD, PhD
NUCLEAR MEDICINE DOCTOR
GENERAL UNIVERSITY HOSPITAL OF PATRAS NUCLEAR MEDICINE DEPARTMENT, Greece
Disclosure information not submitted.
fotis Anagnostopoulos, MD
Interventional Radiology Fellow
2nd Department of Radiology, University General Hospital "ATTIKON" Medical School, National and Kapodistrian University of Athens, Greece
Disclosure information not submitted.
Christos Papageorgiou, MD
Attending
General University Hospital of Patras, Greece
Disclosure information not submitted.
Vasiliki Taki, MD
Resident
General University Hospital of Patras, Greece
Disclosure information not submitted.
Ioannis Spyridonidis, MD, PhD
Attending Radiologist
General University Hospital of Patras, Greece
Disclosure information not submitted.
Evangelia Christodoulou, MD, MS
Resident
General University Hospital Of Patras, Greece
Disclosure information not submitted.
George Kolettis, MD
Resident
General University Hospital of Patras, Greece
Disclosure information not submitted.
Michalis Theofanis, MD
Attending Radiologist
General University Hospital of Patras, Greece
Disclosure information not submitted.
Panagiotis Kitrou, MD, PhD
Asst. Prof. in Interventional Radiology
Patras University Hospital, Greece
Disclosure information not submitted.
Dimitrios Karnabatidis, MD, PhD, EBIR, FCIRSE
Professor in Interventional Radiology
Interventional Radiology, Patras University Hospital, Greece
Disclosure information not submitted.
Konstantinos Katsanos, MD, PhD, MS
Ass Professor
General University Hospital of Patras, Greece
Disclosure information not submitted.
Y90 infusion was performed separately for the liver and the kidney and the total delivered dose was 2.7 GBq in 398mls of tumor. Mean tumor absorbed dose was 158Gy by MIM software dosimetry with immediate control of hematuria. A CT scan at 4 months showed a significant reduction of tumor size (maximum diameter 7.5cm) and complete tumor response by mRECIST criteria. No adverse events were noted.
Conclusion:
Radioembolization is a well-established treatment for unresectable liver tumors. We herein report the safety and efficacy of ablative radioembolization in a large inopeable RCC invading the liver. Large prospective trials are necessary to establish safety and efficacy in non-liver applications.Consider radioembolization for symptomatic relief and local disease control of unresectable RCC.